Adaptation and validation of the Chinese version of the lung cancer screening health belief scales

Yu-an Lin, Lisa Carter-Harris, Jia-ni Yang, Xiu jing Lin and Fei fei Huang*

Abstract
Background: Health belief is an important factor affecting lung cancer screening in high-risk population, but the research based on Chinese cultural background is still insufficient. Therefore, we adapted the English version of the Lung Cancer Screening Health Belief Scales (LCSHB) into the Chinese version (LCSHB-C) and examined its psychometric characteristics.

Methods: After obtaining authorization from the original author, the LCSHB-C was adapted based upon Brislin's translation model. Using a variety of community-based recruitment methods, a total of 353 participants were recruited in Fuzhou, Fujian province, China to complete the questionnaires. We combined the classical test theory and item response theory to examine the psychometric properties of the LCSHB-C.

Results: The Cronbach's alpha for the four subscales ranged from 0.83 ~ 0.93. The content validity index for the four subscales was ranged from 0.87 ~ 1.0. Confirmatory factor analysis supported each subscale structure model fit well. Rasch analysis results further validated the reliability and validity of the four subscales. The person reliability and separation index of each subscale ranged from 0.77 to 0.87 and 1.83 to 2.63, respectively.

Conclusions: The LCSHB-C is a reliable and valid instrument used to measure health beliefs related to lung cancer screening among those high-risk for lung cancer in China, which facilitates the development of lung cancer screening programs and promotes the "three early prevention strategies" of lung cancer (i.e., early detection, early diagnosis and early treatment).

Keywords: Lung Cancer Screening, Health Belief Model, Health beliefs, High-risk population, Reliability, Validity

Background
Lung cancer is the most frequent cancer (2.1 million cases) and the leading cause of cancer-related deaths (1.8 million deaths) for both men and women worldwide [1]. The International Agency for Cancer Research reports that the incidence of lung cancer has been on the rise globally over the past ten years, especially in China. China accounts for the largest number of lung cancer patients in the world [2]. In fact, it is expected that the number of lung cancer patients in China will reach one million by 2025 [3]. Due to the asymptomatic nature of early lung cancer, individuals are often diagnosed at an advanced stage when the prognosis is poor or futile, with only a 12% to 16% relative five-year survival rate [4, 5]. However, if lung cancer can be identified at an early stage, the relative five-year survival rate increases to 60% to 70% [5, 6]. This evidence highlights the importance of secondary prevention for decreasing lung cancer-related mortality.

*Correspondence: pt860315@163.com
1 School of Nursing, Fujian Medical University, Fuzhou, China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
At present, low-dose computed tomography (LDCT) of the chest has been demonstrated to be a sensitive tool for the detection of early stage lung cancer [7]. Annual LDCT screening of the chest for high-risk individuals is recommended by the United States Preventive Services Task Force (Grade B) [8] and the Chinese government [9]. However, globally, screening with LDCT remains vastly underutilized, despite its proven morbidity and mortality benefit [5, 10, 11]. For example, from 2010 to 2015, less than 5% of high-risk individuals (i.e., individuals who currently or formerly smoked long-term) had been screened [10]. From 2018 to 2019, the participation rate of high-risk individuals in lung cancer screening in China was only 6.4% to 31.91% [12, 13].

Prior research has shown that factors related to low screening rates in screening-eligible individuals include psychological and cognitive variables (e.g., stigma, mistrust, fatalism, worry, fear, and low knowledge levels related to lung cancer and lung cancer screening), health beliefs (perceived risk, perceived benefits, perceived barriers, and self-efficacy), healthcare provider recommendation, and social and media exposure [13–15]. Of these factors, health beliefs are an important predictor of lung cancer screening behavior [5, 16]. In other words, the higher level of perceived benefits of, lower level of perceived barriers, and the higher level of self-efficacy, the more likely the individuals will screen for lung cancer screening [5, 11, 16], further supporting important constructions in the Conceptual Model for Lung Cancer Screening Participation [14].

Although research in this area remains early in its trajectory, evidence supporting knowledge and awareness about lung cancer screening remains low, and screening-eligible people continue to have a number of misconceptions regarding lung cancer screening, such as a scan is needed only if one is symptomatic or has not had a chest x-ray [15]. Previous research has also shown that individuals’ age, education level, annual income and health insurance were closely related to the perceived risk of lung cancer, perceived benefits of and perceived barriers to lung cancer screening [15, 17, 18]. However, little is known about the relationship of health beliefs to lung cancer screening participation among high-risk individuals in China, partly owing to the lack of psychometrically validated assessment tools.

Assessment and understanding of individual health beliefs about screening is a critical component to inform future efforts to promote the successful implementation of lung cancer screening programs and maximize the secondary prevention effect of LDCT screening. To our knowledge, the Lung Cancer Screening Health Belief Scales (LCSHB) is one of the few instruments based on the health belief model that can be used to evaluate the perceived risk of lung cancer, perceived benefits of, perceived barriers to, and self-efficacy for lung cancer screening behavior [17]. Although the English version of the LCSHB is found to be psychometrically valid and reliable by classical test theory (CTT), further examination of the scale by item response theory (IRT) may provide more robust evidence [19]. Therefore, the main aim of the current study is to translate the English version of the LCSHB into Chinese and to investigate its psychometric properties with both CTT and IRT methods among the population at high risk for the development of lung cancer in China.

Methods
Participants and settings
From May 2020 to November 2020, participants were recruited using a variety of community-based recruitment methods, such as attaching our questionnaire QR codes on posters or contacting community staff to help post the information on bulletin boards, in Fujian province, China. Eligibility criteria mirrored the Chinese Expert Consensus on the Screening and Management of Lung Cancer [20] and Lung Cancer Screening National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Recommendation [21] for individuals eligible for lung cancer screening and included individuals (1) aged 55 to 74 years and individuals who currently smoke and have a 30 pack-year tobacco smoking history or individuals who used to smoke and have quit within the past 15 years; or (2) ≥ age 40 years and currently smoking with a 20 pack-year tobacco smoking history with one of the following risk factors: a) history of environmental or high-risk occupational exposure (e.g., exposure to asbestos, beryllium, uranium, radon); b) pulmonary disease (e.g., chronic obstructive pulmonary disease, diffuse pulmonary fibrosis or previous history of tuberculosis); c) previous malignant tumor history; d) family history of lung cancer; or e) long-term second-hand smoking exposure.

Participants with previous lung surgery, metal implants or devices in the chest or back, obesity and chest thickness, or diagnosed with lung cancer were excluded. The sample size was determined based on a subject-to-item ratio of 5–10:1 [22] by assuming a non-response rate of 15%, thus the final sample size was 360 potential participants to which the recruitment materials and survey were mailed.

Design and procedures
After written permission was obtained from the original scale developer (Carter-Harris), we translated the LCSHB into the Chinese version (LCSHB-C) and then examined the psychometric properties of the LCSHB-C,
which were found to be adherent to the COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) checklist [23, 24]. We applied Brislin’s translation model to the cross-cultural translation, which includes translation, back-translation, comparison, and linguistic adaption [25, 26], as showed in Fig. 1. When we compared the original and back-translated versions, we found four items in discrepancy and were re-translated and back-translated, including I7 “I might put off having a lung scan because transportation would be a problem.” (B7. I may postpone the lung scan because traffic will be a problem.); I14 “I might postpone the lung scan because I worry about feeling like a social outcast for smoking.” (B14. I may postpone the lung scan because I am worried that I feel like a person abandoned by society because of smoking.); I15 “I might put off having a lung scan because I worry about being blamed for having smoked.” (B15. I may postpone the lung scan because I worry about being blamed for having smoked.); I28 “Compared to other people your same age who have never smoked, what would you say your risk of getting lung cancer is” (B28. Compared with other people who are the same age but not smoking, you think that your risk of lung cancer is).

In the stage of pilot testing, the interview used structured probes to uncover how participants interpreted items of the LCSHB-C to verify its comprehensibility and readability. Example probes included: “Tell me in your own words what this question is asking,” “How did you decide on your answer to this question?” and “What does [health beliefs about lung cancer screening] mean to you?” Interviews were audio recorded and transcribed verbatim. None of the participants reported confusion or incomprehension about any of the scale items. After this process, the LCSHB-C was ready for validation. In the survey, we adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [27].

**Ethical considerations**
The research was approved by the institutional review board of Fujian Medical University (Grant number: FM2020097), and written informed consents were obtained from all participants. Finally, a total of 353 participants enrolled and completed the 15-min survey and received a $10 gift card at completion. Participant anonymity was preserved in all cases. 

**Data collection**
Data were all collected through online surveys with QR codes on posters or bulletin boards by Wenjuanxi (the most popular online data collection platform in China, available at [https://www.wjx.cn/]). The study aim and data collection procedure were fully explained to the participants.

**Measures**

*LCSHB-C*
The LCSHB-C consists of 35 items in total to evaluate an individuals’ lung cancer screening health beliefs in the following four domains represented by the four subscales: (1) perceived risk of lung cancer, (2) perceived benefits of, (3) perceived barriers to, and (4) self-efficacy
for lung cancer screening. All items in the perceived risk, perceived benefits, and perceived barriers subscales use a 4-point Likert scale (1 = strongly disagree to 4 = strongly agree) response option, and items in the self-efficacy subscale use the 4-point Likert scale of 1 = not at all confident to 4 = very confident. Items are all positively worded, and the total score is obtained by summing the scores of all items in each subscale. A higher total score on each individual subscale indicates higher perceived lung cancer screening health beliefs (perceived risk, perceived benefits, perceived barriers, and self-efficacy, respectively). The Cronbach’s alpha values ranged from 0.88 to 0.92 for the 4 subscales [17].

**Lung cancer and screening knowledge questionnaire**

This questionnaire was used to assess individuals’ knowledge for lung cancer and screening, which was adapted from Carter-Harris’ knowledge scale [18]. The questionnaire includes five questions with binary scoring (“correct” = 1, “wrong” = 0). The total score ranges from 0 to 5, and a higher total score indicates greater knowledge about lung cancer screening.

**Socio-demographic questionnaire**

We also collected participants’ age, gender, marital status, educational level, monthly household income (yuan, RMB), residential location, religious belief, employment status, body mass index (BMI), health insurance, smoking status, family history of cancer, and frequency of lung cancer screening.

**Data analysis**

Data analyses were conducted using SPSS 23.0 (IBM, Chicago, IL, USA) and WINSTEPS 3.75.0 (Chicago, IL, USA) with a p-value < 0.05 was considered significant. Missing values were replaced using the multiple imputation calculation [28].

a) Cross-cultural validity: The 4-point COSMIN checklist [29] was used to measure whether the description of the translation scale well reflected the items in the original scale [23, 24].

b) Content validity: Content validity was evaluated from the translation validity index (TVI) adapted from the content validity index (CVI) described by Tang and Dixon [30]. A four-point scale was employed to rate the translational relevance of each item on the four subscales (1 = “totally different” to 4 = “equivalent”). The item TVI (I-TVI) was calculated by dividing the number of experts with a relevance rating of 3 or 4 by the total number of experts. And the mean value of TVI for each item was the TVI of the total scale (STVI).

c) Structural validity: Confirmatory factor analysis (CFA) in CTT and Rasch analyses were performed in combination to assess the construct validity of the scale. In the CFA, the best fitting model of each subscale was tested using the maximum likelihood method. Absolute and relative indices [31, 32], including normed χ² (χ²/df) between 1.0 and 3.0, Root Mean Square Error of Approximation (RMSEA; < 0.08), Comparative Fit Index (CFI), Tucker-Lewis Index (TLI), and Normed Fit Index (NFI) > 0.9, were employed to evaluate the model's goodness of fit. In Rasch analysis, the unidimensionality assumptions were first checked by the first contrast of the residual to ensure that it was not higher than 2 [19] and then the rating scale model (RSM) was used to assess person/item separation reliability, person/item separation index, category probability curves, test information functions and person-fit statistics [33, 34]. Infit and outfit mean squares, as well as difficulty (location) for individual items were involved in Pearson’s fit statistics [35]. Items were tested for the differential item functioning (DIF) by gender (male and female).

d) Construct validity: We estimated the convergent validity of the four subscales of the LCSHB-C using Pearson’s correlations, with expected significant positive correlations with the lung cancer and screening knowledge total score.

e) Known-group validity: Known-group validity was performed by determining whether the subscale scores of the LCSHB-C could discriminate among participants with different frequency of lung cancer screening participation behaviors.

f) Internal consistency: We used Cronbach’s alpha to assess the internal consistency reliability of the four subscales [32].

g) Floor/ceiling effect: Floor effects were evaluated by examining the percentage of the respondents that achieved the lowest possible scores. Ceiling effects were evaluated by examining the percentage of respondents that reached the highest possible score.

**Results**

**Participants characteristics**

A total of 353 valid questionnaires were returned out of the 360 questionnaires distributed (response rate, 98.06%). Descriptive statistics were reported using the medial and inter-quartile ranges due to the non-normality. For example, the age, smoking pack-years and BMI of the participants were 45 years (44.0, 52.0), 27.4
pack-years (27.4, 34.8) and 23.04 kg/m² (21.0, 26.3), respectively. See Table 1 for a complete list of participant socio-demographic characteristics.

CTT Validity Testing of the LCSHB-C

Cross-cultural validity

The process of translation and the sample size (≥ 150) met the requirements of “adequate” in the COSMIN checklist [29].

Content Validity of the LCSHB-C

Five experts were consulted (All with doctoral degree and have well working experience on nursing and public health). Expert consultation demonstrated that S-TV1 ranged from 0.87 to 1.0 for four subscales.

Structural Validity of the LCSHB-C

As shown in Fig. 2, the single-factor models of perceived barriers to lung cancer screening subscale, perceived risk of lung cancer subscale, perceived benefits of lung cancer screening subscale, and self-efficacy for lung cancer screening subscale were fit well and confirmed by CFA. The model fit indices of the LCSHB-C subscale models are shown in Table 2.

Construct Validity of the LCSHB-C

Pearson’s correlation analysis showed that the subscale score of perceived benefits of lung cancer screening and self-efficacy for lung cancer screening was significantly positively correlated with the lung cancer and screening knowledge score ($r = 0.203, 0.154, 0.230, p < 0.01$), respectively. However, both the perceived barriers to lung cancer screening score and the perceived risk of lung cancer score was not correlated with the total knowledge score in this sample.

Known-group validity of the LCSHB-C

We found that there were no significant differences between screeners and non-screeners for perceived barriers and perceived risk scores, but screeners had significantly higher perceived benefits, and self-efficacy (see Table 3).

Floor/ceiling effect

As shown in Table 4, the four subscales have a lack of floor or ceiling effects, that is, the occurrences of the lowest and highest possible four subscale scores were both below 15%.

Rasch Analysis of the LCSHB-C

In the Rasch analysis, the unidimensionality assumption of each subscale was supported by the first contrast of the residual ranging from 1.7 to 2.0 (less than 2). As shown in Table 5, the infit and outfit mean squares for each item ranged from 0.63 to 1.43. The differential item functioning was not found when evaluated by gender. No evidence of disordered thresholds was found in the category probability curves, as the category calibration increased in an orderly way (see Appendix A). We also found the item reliability and separation index was 0.82(2.37), 0.81(2.14), 0.94(3.88), and 0.72(2.00), and person reliability and separation index was 0.85(2.41), 0.82(2.15), 0.77(1.83), 0.87(2.63) for the barriers, benefits, risk and self-efficacy subscales, respectively. Regarding the test information functions, both subscales gathered information most precisely when $\Theta$ ranged from 0 to 2.0 (see Appendix B).

Reliability of the LCSHB-C

The Cronbach’s alpha for the subscale of perceived barriers to lung cancer screening, perceived risk of lung cancer, perceived benefits of lung cancer screening, and self-efficacy for lung cancer screening were 0.88, 0.90, 0.83, and 0.93.

Discussion

This study adapted and validated the LCSHB scales to Chinese, following standard translation and cultural adaptation guidelines [36]. Our psychometric evaluation, based on the CTT and Rasch analysis, showed that the LCSHB-C (perceived risk, perceived benefits, perceived barriers, self-efficacy) can provide sufficient validity (cross-cultural validity, structural validity and construct validity), satisfactory internal consistency reliability, without no floor/ceiling effect. The reliable and valid LCSHB-C will contribute to a more accurate evaluation and in-depth understanding of the levels and types of health beliefs for lung cancer screening among individuals at risk for the development of lung cancer who speak Chinese. Improving health beliefs in a population at high-risk for the development of lung cancer can ultimately improve the lung cancer screening decision-making process and subsequent screening behavior [14]. Thus, the Chinese version of LCSHB scales can now inform tailored intervention development as well as programmatic efforts to increase lung cancer screening uptake in the high-risk Chinese population.

This study demonstrated the applicability of the LCSHB scales for the high-risk population of lung cancer in China and its good reliability and validity based on CTT and Rasch analysis. Interestingly, we found that the Chinese and English versions of the LCSHB shared the
Table 1  The participant socio-demographic characteristics (n = 353)

| Characteristic                                      | n(%)  |
|-----------------------------------------------------|-------|
| Gender                                              |       |
| Male                                                | 284(80.45) |
| Female                                              | 69(19.55)  |
| Residential location                                |       |
| Urban                                               | 197(55.81) |
| Suburban                                            | 59(16.71)  |
| Rural                                               | 97(27.48)  |
| Educational level                                   |       |
| Primary school degree or below                      | 56(15.86)  |
| Middle school degree                                | 78(22.10)  |
| Technical school/college degree                     | 143(40.51) |
| Bachelor's degree or higher                         | 76(21.53)  |
| Religious belief                                    |       |
| No religion                                         | 177(50.14) |
| Christianity                                        | 44(12.46)  |
| Buddhism                                            | 124(35.13) |
| Islamism                                           | 6(1.70)  |
| Others(e.g. Taoism)                                 | 2(0.60)  |
| Employment status                                   |       |
| worker                                              | 49(13.88)  |
| farmer                                              | 89(25.21)  |
| Administrative cadre                                | 43(12.18)  |
| Science and technology - medical personnel or teacher| 49(13.88)  |
| Individual, business, enterprise or service personnel| 103(29.18) |
| Retired                                             | 13(3.68)  |
| Housewife                                           | 6(1.70)  |
| Others a                                            | 10(0.28)  |
| Occupational exposure b                             |       |
| Yes                                                 | 208(58.92) |
| No                                                  | 145(41.08) |
| Medical insurance                                   |       |
| Self-paid (uninsured)                               | 42(11.90)  |
| Provincial medical insurance                        | 73(20.68)  |
| Municipal medical insurance                         | 99(28.05)  |
| New agricultural cooperative medical insurance       | 138(39.09) |
| Others(e.g. medical insurance for urban employees)  | 10(0.28)  |
| Monthly household income (yuan, RMB)                |       |
| < 1000                                              | 30(8.50)  |
| 1000–2999                                           | 87(24.65)  |
| 3000–4999                                           | 123(34.84) |
| > 5000                                              | 113(32.01) |
| Smoking status                                      |       |
| current smoker                                      | 267(75.64) |
| Former smoker (now quit)                            | 86(24.36)  |
| Smoking status of family members                    |       |
| current smoker                                      | 286(81.02) |
| Former smoker (now quit)                            | 67(18.98)  |
| History of lung disease                             |       |
| Yes                                                 | 58(16.43)  |
| No                                                  | 295(83.57) |
| Metal implants or devices in your chest or back      |       |
| Yes                                                 | 100(28.33) |
| No                                                  | 253(71.67) |
| Suffering from cancer                               |       |
| Yes                                                 | 12(3.40)  |
| No                                                  | 341(96.60) |
| Family history of cancer                            |       |
| No                                                  | 273(77.34) |
| Unclear                                             | 65(18.41)  |
| Yes                                                 | 13(4.25)  |
| Frequency of lung cancer screening                   |       |
| Never                                               | 142(40.23) |
| Every year                                          | 147(41.64) |
| Uncertain                                           | 64(18.13)  |

a  blacksmith

b  Such as asbestos, chromate, coke oven efflux, arsenic, chloromethyl ether, radon and its progeny, radiation, silica, beryllium, uranium, radon and other substances
Table 2  The model fit indices of the LCSHB-C scale and subscale models

| Model                                      | $\chi^2$ | $\chi^2$/df* | RMSEA | CFI  | TLI  |
|--------------------------------------------|----------|---------------|-------|------|------|
| The perceived barriers of LCS subscale model | 318.03   | 2.79          | 0.07  | 0.88 | 0.87 |
| The perceived benefits of LCS subscale model | 18.56    | 2.65          | 0.07  | 0.99 | 0.98 |
| The perceived risk of LCS subscale model   | 3.13     | 0.78          | 0.00  | 0.99 | 0.99 |
| The self-efficacy for LCS subscale model   | 83.25    | 3.33          | 0.08  | 0.97 | 0.96 |

LCS lung cancer screening, *$p < 0.05$

Table 3  Scale means examining differences between participants who have Screened for lung cancer and unscreened

| Scale Range | Overall (n = 353) Mean (SD) | Screeners (n = 211) Mean (SD) | Non-screener (n = 142) Mean (SD) | T value ($p$ value) |
|-------------|-----------------------------|-------------------------------|----------------------------------|--------------------|
| Total perceived barriers scores            | 17–68                       | 40.10(8.48)                   | 40.21(8.13)                   | 39.92(9.01)        | 0.32(0.75)        |
| Total perceived benefits scores            | 6–24                        | 17.80(3.88)                   | 18.24(3.83)                   | 17.14(3.89)        | 2.63(0.01)*       |
| Total perceived risk scores                | 3–27                        | 6.93(2.29)                    | 7.11(2.28)                    | 6.67(2.29)         | 1.78(0.08)        |
| Total self-efficacy scores                 | 9–36                        | 26.44(6.16)                   | 27.64(5.71)                   | 24.64(6.38)        | 4.62(0.00)*       |

SD standard deviation, *$p < 0.05$
same factor structure [17]. Confirmed with the expanded health belief model [37], our findings indicated that the LCSHB scales can adequately measure perceived risk of lung cancer, perceived benefits of, perceived barriers to, and self-efficacy for lung cancer screening among the high-risk population at high risk for the development of lung cancer in China.

Similar to prior work [17], we found that screeners had higher health beliefs related to lung cancer screening.

### Table 4 The floor/ceiling effect analysis of four subscales

| Subscale            | Score ranges | Lowest score (%) | Highest score (%) |
|---------------------|--------------|------------------|-------------------|
| Perceived barriers  | 17–68        | 1.4%(5/353)      | 1.7%(6/353)       |
| Perceived benefits  | 6–24         | 2.3%(8/353)      | 10.8%(38/353)     |
| Perceived risk      | 3–12         | 11.6%(41/353)    | 3.7%(13/353)      |
| Self-efficacy       | 9–36         | 2.5%(9/353)      | 11.3%(40/353)     |

### Table 5 The Rasch analysis of the LCSHB-C

| Subscale                              | Item   | Item difficulty a | Infit MNSQ | Outfit MNSQ | DIF contrast by genderb |
|---------------------------------------|--------|-------------------|------------|-------------|-------------------------|
| Perceived barriers to lung cancer screening | B1     | 0.10              | 1.26       | 1.43        | 0.82                    |
|                                       | B2     | 0.00              | 0.90       | 0.90        | 1.72                    |
|                                       | B3     | 0.02              | 0.97       | 1.04        | 1.71                    |
|                                       | B4     | -0.17             | 1.17       | 1.25        | 1.35                    |
|                                       | B5     | -0.01             | 0.95       | 0.94        | 0.06                    |
|                                       | B6     | -0.03             | 1.03       | 1.04        | 0.55                    |
|                                       | B7     | -0.02             | 1.00       | 1.01        | 0.28                    |
|                                       | B8     | -0.01             | 0.94       | 1.00        | 0.01                    |
|                                       | B9     | -0.01             | 0.91       | 0.92        | 0.89                    |
|                                       | B10    | -0.06             | 0.93       | 0.96        | 1.69                    |
|                                       | B11    | -0.14             | 0.85       | 0.87        | 0.03                    |
|                                       | B12    | 0.01              | 1.17       | 1.33        | 2.15                    |
|                                       | B13    | 0.07              | 0.88       | 0.87        | 0.42                    |
|                                       | B14    | 0.04              | 0.93       | 0.92        | 0.04                    |
|                                       | B15    | 0.01              | 0.81       | 0.81        | 2.1                     |
|                                       | B16    | 0.01              | 1.02       | 1.06        | 1.19                    |
|                                       | B17    | 0.21              | 1.26       | 1.40        | 1.77                    |
| Perceived benefits of lung cancer screening | Be1    | -0.17             | 1.12       | 1.04        | 0.57                    |
|                                       | Be2    | 0.02              | 0.94       | 0.88        | 0.52                    |
|                                       | Be3    | 0.16              | 1.14       | 1.11        | 2.38                    |
|                                       | Be4    | 0.04              | 0.92       | 0.83        | 0.39                    |
|                                       | Be5    | -0.08             | 0.93       | 0.83        | 0.18                    |
|                                       | Be6    | 0.03              | 0.92       | 0.83        | 0.01                    |
| Perceived risk of lung cancer screening | R1     | -0.68             | 1.38       | 1.38        | 0.30                    |
|                                       | R2     | 0.14              | 0.66       | 0.63        | 0.42                    |
|                                       | R3     | 0.54              | 0.91       | 0.89        | 0.01                    |
| Self-efficacy for lung cancer screening | S1     | 0.32              | 1.21       | 1.26        | 1.66                    |
|                                       | S2     | 0.10              | 0.89       | 0.89        | 0.00                    |
|                                       | S3     | -0.11             | 1.10       | 1.12        | 0.15                    |
|                                       | S4     | -0.14             | 0.90       | 0.88        | 0.59                    |
|                                       | S5     | -0.12             | 0.92       | 0.90        | 0.75                    |
|                                       | S6     | 0.05              | 0.87       | 0.86        | 1.87                    |
|                                       | S7     | -0.11             | 0.96       | 0.93        | 0.40                    |
|                                       | S8     | -0.03             | 1.06       | 1.02        | 0.41                    |
|                                       | S9     | 0.05              | 1.06       | 1.04        | 0.37                    |

*MNSQ mean square

a Measured in logit; positive item logit indicates that the item requires a lower visual ability than the mean of the items and is an easier item; a negative item logit indicates that the item requires a higher visual ability than the mean of the items and is a more difficult item

b male compared with female
(i.e., perceived benefits, self-efficacy) than non-screeners, which extends the work of Carter-Harris and colleagues by supporting consistency between the original work in an English-speaking American population and a Mandarin-speaking Chinese population. The significance of this work lies in the ability to validly measure health beliefs in the high-risk Chinese population to identify potentially modifiable individual-level factors on which to intervene in future lung cancer screening outreach programs. In addition, construct validity of the LCSHB-C was also supported by the significant positive correlations with the total lung cancer screening knowledge scale score, which is consistent with the previous work [18]. Finally, internal consistency reliability was supported with all 4 subscales noting a Cronbach’s alpha more than 0.70 [32].

Apart from the traditional CTT methods, we also examined the construct validity of LCSHB-C by Rasch analysis, with the results showing that the category rating scale of the LCSHB-C was in good operation. Besides, LCSHB-C with acceptable measurement precision is sensitive to differentiating between high and low levels of health beliefs associated with LCS according to the results of the combination of a good person-separation index (>2) and person reliability (>0.8) [34].

**Limitation**

As with all studies, this study is not without limitations. First, participants were recruited from one province in China which may impact generalizability to all Chinese individuals and that future work that examines health beliefs across geographically diverse areas of China is warranted. Second, the inclusion criteria of this study mainly referred to the Chinese Expert Consensus on the Screening and Management of Lung Cancer [20], which differed from the inclusion criteria of the original scale in two aspects. The younger age of the participants might be related to the fact that online surveys were mostly conducted by younger groups. On the other hand, the smoking history was relatively light, which might be related to the greater health awareness of the included participants, with nearly 56% of the people surveyed coming from urban areas. Therefore, the sample may be not representative enough. Future studies can not only adopt the method of the on-site survey to better understand the difference of participants between the two routes of completion but also pay more attention to an older group or those in rural and suburban areas, such as recruiting through recommendation from community healthcare providers or adopting stratified sampling. Third, some psychometric characteristics of the LCSHB-C could be assessed further, such as test–retest reliability. Moreover, the sensitivity of the LCSHB-C subscales was not assessed. Therefore, future longitudinal or experimental studies are warranted. A further refinement of the scale based on a larger representative sample will produce more stable parameter estimations and robust results.

**Conclusions**

The Chinese version of LCSHB scale comprised of four subscales is a sufficiently valid and reliable tool for assessing health beliefs for lung cancer screening among the populations at greatest risk for the development of lung cancer in China. The scales can also contribute to a better understanding of how health beliefs in the context of lung cancer screening operate within high-risk populations who make the decision to screen, or not, for lung cancer in China. Finally, the LCSHB-C can also inform the development of lung cancer screening outreach programs by providing a psychometrically valid tool to evaluate the effects of such programs.

**Relevance for clinical practice**

Evidence has consistently indicated that individual health belief about screening is a common barrier to the uptake of the secondary prevention of lung cancer screening—especially among those with a high disease burden related to lung cancer in China [5]. Community nurses and local healthcare providers can use the LCSHB-C to accurately measure perceived risk of lung cancer, perceived benefits of, perceived barriers to, and self-efficacy for lung cancer screening behavior. Furthermore, this scale can also facilitate the development of lung cancer screening outreach programs and evaluate the effects of future interventions. Additional research with more representative samples is needed to further examine the screening utility of this scale. It will also be important to determine the cut-off value for the LCSHB-C subscales (low, middle, and high levels of the four health beliefs for lung cancer) and to compare the health belief for screening among high-risk individuals of lung cancer globally.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-13041-y.

**Acknowledgements**

We gratefully acknowledge all the study participants, without them, it is not possible to complete the study.

**Authors’ contributions**

Fei fei Huang, the correspondence author of this study, was responsible for designing, guiding, organizing, and planning this study. Yu-an Lin and Lisa Carter-Harris were responsible for the scale translation and manuscript...
preparation. Jia-ni Yang and Xiu jing Lin were responsible for data collection and data analysis. The author(s) read and approved the final manuscript.

Funding
This work was supported by the undergraduate students' innovation and entrepreneurship training program of Fujian province (Grant NO. S202010392025) and General Project of Fujian Provincial Nature Science Foundation (Grant NO.2021J01246).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The research was approved by the institutional review boards of Fujian Medical University (Grant number: FM2020097), and written informed consents were obtained from all participants. All methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).

Consent for publication
Not applicable.

Competing interests
The authors have no conflicts of interest to disclose.

Author details
1 School of Nursing, Fujian Medical University, Fuzhou, China. 2 Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Received: 15 October 2021 Accepted: 22 March 2022
Published online: 30 March 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
2. Cheng YT, Davies MP, Liu D, Li W, Field JK. Implementation planning for lung cancer screening in China. Precision Clinical Medicine. 2019;2(1):13–44. https://doi.org/10.1093/pcmd/pbz002.
3. Li J, Su K, Li F, Tang W, Huang Y, Wang L, et al. Systematic review of the methodology quality in lung cancer screening guidelines. Chin J Lung Cancer. 2016;19(10):692–9. https://doi.org/10.3779/jissn.1009-3419.2016.10.11.
4. American Cancer Society. Cancer facts & figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed Aug 2021
5. Lei F, Lee E. Barriers to lung cancer screening with low-dose computed tomography. Oncol Nurs Forum. 2019;46(2):E60–71. https://doi.org/10.1188/19.ONF.E60-E71.
6. Wang Z, Han W, Zhang W, Xue F, Wang Y, Hu Y, et al. Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice. Chin J Cancer. 2017;36(1):57. https://doi.org/10.1186/s40880-017-0221-8.
7. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, Paskiander MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–71. https://doi.org/10.1056/NEJMoa060476.
8. US Preventive Services Task Force. Screening for lung cancer: us preventiveservices task force recommendation statement. JAMA. 2021;325(10):962–70. https://doi.org/10.1001/jama.2021.1117.
9. Zhao DW, Hu YC. Chinese experts’ consensus on the diagnosis and treatment of osteonecrosis of the femoral head in adults. Orthop Surg. 2012;4(3):125–30. https://doi.org/10.10111/j.1757-7861.2012.00192.x.
10. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States-2010 to 2015. JAMA Oncol. 2017;3(9):1278–81. https://doi.org/10.1001/jamaoncol.2016.6416.
11. Monu J, Triplette M, Wood DE, Wolff EM, Lavalice DC, Flum DR, et al. Evaluating knowledge, attitudes, and beliefs about lung cancer screening using crowdsourcing. Chest. 2020;158(1):386–92. https://doi.org/10.1016/j.chest.2019.12.048.
12. Lin YP, Ma J, Feng J, Zhang Q, Huang YC. Results of lung cancer screening among urban residents in Kunming. Chin J Lung Cancer. 2019;22(7):413–8. https://doi.org/10.3779/jissn.1009-3419.2019.07.02.
13. Lu Z, Men, Zhang T, Zhao LH, Chen GA, Wei DH, Zhang JQ, et al. The relationship between demands for lung cancer screening and the constructs of health belief model: a cross-sectional survey in Hefei. China Psychol Health Med. 2018;23(8):934–51. https://doi.org/10.3745806.2018.1428757.
14. Carter-Harris L, Davis LL, Rawl SM. Lung cancer screening participation: developing a conceptual model to guide research. Res Theory Nurs Pract. 2016;30(4):333–52. https://doi.org/10.1891/1541-6579.30.4.333.
15. Draucker CB, Rawl SM, Vode E, Carter-Harris L. Understanding the decision to screen for lung cancer or not: a qualitative analysis. Health Expect. 2019;22(6):1314–21. https://doi.org/10.1111/hec.12975.
16. Bui NC, Lee YY, Suh M, Park B, Cho H, Kim Y, et al. Beliefs and intentions to undergo lung cancer screening among Korean Males. Cancer Res Treat. 2018;50(4):1096–105. https://doi.org/10.4143/crt.2017.393.
17. Carter-Harris L, Slaven JE 2nd, Monohan P, Rawl SM. Development and psychometric evaluation of the lung cancer screening health belief scales. Cancers. 2017;4(3):237–44. https://doi.org/10.3979/JNCC.0000000000000386.
18. Carter-Harris L, Slaven JE 2nd, Monohan PO, Draucker CB, Vode E, Rawl SM. Understanding lung cancer screening behaviour using path analysis. J Med Screen. 2020;27(2):103–12. https://doi.org/10.1177/0969141319876961.
19. Leung YY, Png ME, Conaghan P, Tennant A. A systematic literature review on the application of Rasch analysis in musculoskeletal disease – a special interest group report of OMERACT 11. J Rheumatol. 2014;41(1):159–64. https://doi.org/10.3899/jrheum.130819.
20. Chinese Alliance Against Lung Cancer, Chinese Medical Association of Respiratory Disease Branch Lung Cancer Study Group, Chinese Medical Doctor Association of Respiratory Doctor Branch Lung Cancer Working Committee. Chinese expert consensus on screening and management of lung cancer. International Journal of Respiration. 2019;39(21):1604–15. https://doi.org/10.3760/cma.j.issn.1673-483X.2019.21.002.
21. Wood DE, Kazerooni EA, Baum SL, Epenyi GA, Erttnger DS, Hou L, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(4):412–41. https://doi.org/10.6004/jnccn.2018.0020.
22. Steiner DL, Norman GR, Caimey J. Health measurement scales: a practical guide to their development and use. 5th ed. Oxford: Oxford University Press; 2015.
23. Mokkink LB, Terwee CB, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49. https://doi.org/10.1007/s11136-010-0966-6.
24. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737–45. https://doi.org/10.1016/j.jclinepi.2010.02.006.
25. Brislin RW. Back-translation for cross-cultural research. J Cross-Cult Psychol. 1970;1(3):187–216. https://doi.org/10.1177/0022022170010303.
26. Jones PS, Lee JW, Phillips LR, Zhang XE, Jaceldo KB. An adaptation of Brislin’s translation model for cross-cultural research. Nhrs Res. 2001;50(5):330–4. https://doi.org/10.1007/00006199-20010900-00008.
27. von Elm E, Altman DG, Egger M, Pocock SJ, GPC, Vandenbroucke JP. STROBE initiative: the strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9. https://doi.org/10.1016/j.ijsu.2014.07.013.
28. Patrician PA. Multiple imputation for missing data. Res Nurs Health. 2002;25(1):76–84. https://doi.org/10.1002/nur.10015.
29. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651–7. https://doi.org/10.1007/s11136-011-9960-1.

30. Tang ST, Dixon J. Instrument translation and evaluation of equivalence and psychometric properties: the Chinese sense of coherence scale. J Nurs Meas. 2002;10(1):59–76. https://doi.org/10.1891/jnum.10.1.59.52544.

31. Huang FF, Yang Q, Han XY, Zhang JP, Lin T. Development and validation of a self-efficacy scale for postoperative rehabilitation management of lung cancer patients. Psycho-Onkol. 2017;26(8):1172–80. https://doi.org/10.1002/pon.4296.

32. Johnson C, Aaronson N, Blazeby JM, Bottomley A, Fayers P, Koller M, et al. Guidelines for developing questionnaire modules. 4th ed. Brussels: EORTC: On behalf of the Quality of Life Group; 2011.

33. Linacre JM. Winsteps Rasch Measurement Computer Program User’s Guide. Beaverton: Winsteps.com; 2015.

34. Xu Z, Wu S, Li W, Dou Y, Wu Q. The Chinese Catquest-9SF: validation and application in community screenings. BMC Ophthalmol. 2018;18(1):77. https://doi.org/10.1186/s12886-018-0743-0.

35. Baker FB. The Basics of Item Response Theory. 2nd ed. ERIC Clearinghouse on Assessment and Evaluation. College Park: University of Maryland; 2001.

36. Ye QM, Liu K, Bu XQ, Zhang LF. Cross-cultural adjustment of scales in cross-cultural research. Chinese Journal of Practical Nursing. 2014;30(32):62–4. https://doi.org/10.3760/cma.j.issn.1672-7088.2014.32.018.

37. Rosenstock IM. Why people use health services. Milbank Mem Fund Q. 1966;44(3):94–127 (PMID: 5967464).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.